EUVIMEDEUVIMED entdecken
Crossref

487P Real-world outcomes to frontline standard of care gemcitabine/cisplatin plus durvalumab in IDH1 mutated advanced cholangiocarcinoma in the US

A. Lamarca, R.D. Kim, J. Al Azzi, C. Sofeu, D. Yi, S. Lee

Annals of Oncology · 2026-12 · 37 · S554

DOI: 10.1016/j.annonc.2026.08.577 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Oncology, 2026-12. Verfasst von A. Lamarca und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Lamarca, A., Kim, R., Azzi, J. A., Sofeu, C., Yi, D., & Lee, S. (2026). 487P Real-world outcomes to frontline standard of care gemcitabine/cisplatin plus durvalumab in IDH1 mutated advanced cholangiocarcinoma in the US. Annals of Oncology, 37, S554. https://doi.org/10.1016/j.annonc.2026.08.577

Vancouver

Lamarca A, Kim R, Azzi JA, Sofeu C, Yi D, Lee S. 487P Real-world outcomes to frontline standard of care gemcitabine/cisplatin plus durvalumab in IDH1 mutated advanced cholangiocarcinoma in the US. Annals of Oncology. 2026;37:S554. doi:10.1016/j.annonc.2026.08.577

BibTeX
@article{Lamarca2026,
  author = {Lamarca, A. and Kim, R.D. and Azzi, J. Al and Sofeu, C. and Yi, D. and Lee, S.},
  title = {487P Real-world outcomes to frontline standard of care gemcitabine/cisplatin plus durvalumab in IDH1 mutated advanced cholangiocarcinoma in the US},
  journal = {Annals of Oncology},
  year = {2026},
  volume = {37},
  pages = {S554},
  doi = {10.1016/j.annonc.2026.08.577}
}
Kostenlos starten →